Are inhaled systemic therapies a viable option for the treatment of the elderly patient?

Drugs and Aging

Volumn 25, Issue 2, 2008, Pages 89-94

  Allen, Stephen ^a,b  

^a BOURNEMOUTH UNIVERSITY   (United Kingdom)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Elderly; Inhalation; Inhaler devices

Indexed keywords

INSULIN;

AGING; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; DRUG ABSORPTION; ELDERLY CARE; FRAIL ELDERLY; HUMAN; INHALATION; INHALER; LUNG FUNCTION; MENTAL HEALTH; NOSE CAVITY; PRIORITY JOURNAL; REVIEW; SMOKING; TECHNOLOGY; UPPER RESPIRATORY TRACT;

EID: 38949186557     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825020-00001     Document Type: Review

References (73)

1. Booth M. Opium: a history [online]. Available from URL: http://opioids.com [Accessed 2007 Mar 20]
2. Borio G. The tobacco timeline [online]. Available from URL: http://www.tobacco.org/History/Tobacco_History.html [Accessed 2007 Dec 10]
3. Sanders M. Inhalation therapy: an historical perspective. Prim Care Respir J 2007; 16 (2): 71-81
4. Howell TH. King Solomon's portrait of old age by John Smith. Age Ageing 1987; 16: 321-7
5. Laqueur E, Grevenstuk A. Uber die Wirkung intratrachealer Zufuhrung von Insulin. Klin Wochenschr 1924; 328: 1273-4
6. Mahesh Kumar T, Misra A. Formulation and evaluation of insulin dry powder for inhalation. Drug Dev Ind Pharm 2006; 32 (6): 677-86
7. Bellary S, Barnett AH. Inhaled insulin (Exubera® ): combining efficacy and convenience. Diab Vasc Dis Res 2006; 3 (3): 179-85
8. Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term (review). Prescrire Int 2006; 15 (86): 203-9
9. Del Prato S. Inhaled insulins: the present and future of diabetes therapy. Curr Med Res Opin 2006; 22 Suppl. 3: 13-9
10. Fabbri L. Pulmonary safety of inhaled insulins: a review of the current data. Curr Med Res Opin 2006; 22 Suppl. 3: 21-8
11. Royle P, Waugh N, McAuley L, et al. Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2004; (3): CD003890
12. de Galan BE, Simsek S, Tack CJ, et al. Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus. Neth J Med 2006; 64 (9): 319-25
13. Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145 (9): 665-75
14. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Res 2006; 58 (9-10): 1009-29
15. Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006; 113 (1): 9-14
16. Sakagami M, Byron PR. Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin Pharmacokinet 2005; 44 (3): 263-77
17. Gaber NN, Darwis Y, Peh KK, et al. Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate. J Nanosci Nanotechnol 2006; 6 (9-10): 3095-101
18. Vyas SP, Kannan ME, Jain S, et al. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004; 269 (1): 37-49
19. Edwards DA, Dunbar C. Bioengineering of therapeutic aerosols. Annu Rev Biomed Eng 2002; 4: 93-107
20. Walde P, Ichikawa S. Enzymes inside lipid vesicles: preparation, reactivity and applications. Biomol Eng 2001; 18 (4): 143-77
21. Gonda I. Systemic delivery of drugs to humans via inhalation. J Aerosol Med 2006; 19 (1): 47-53
22. Mu L, Teo MM, Ning HZ, et al. Novel powder formulations for controlled delivery of poorly soluble anticancer drug: application and investigation of TPGS and PEG in spray-dried particulate system. J Control Release 2005; 103 (3): 565-75
23. Thipphawong J. Inhaled cytokines and cytokine antagonists. Adv Drug Deliv Rev 2006; 58 (9-10): 1089-105
24. Chougule MB, Padhi BK, Misra A. Nano-liposomal dry powder inhaler of amiloride hydrochloride. J Nanosci Nanotechnol 2006; 6 (9-10): 3001-9
25. Ely L, Roa W, Finlay WH, et al. Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm 2007; 65 (3): 346-53
26. Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Release 2005; 104 (1): 79-90
27. He P, Davis SS, Illum L. Sustained release chitosan microspheres prepared by novel spray drying methods. J Microencapsul 1999; 16 (3): 343-55
28. Smaldone GC. Smart nebulizers. Respir Care 2002; 47 (12): 1434-41
29. Lipworth BJ, Clark DJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulm Pharmacol Ther 1997; 10 (4): 211-4
30. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 2004; 1 (4): 315-20
31. Scheuch G, Kohlhaeufl MJ, Brand P, et al. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006; 58 (9-10): 996-1008
32. Bennett WD, Brown JS, Zeman KL, et al. Targeting delivery of aerosols to different lung regions. J Aerosol Med 2002; 15 (2): 179-88
33. Bennett WD. Aerosolized drug delivery: fractional deposition of inhaled particles. J Aerosol Med 1991; 4 (3): 223-7
34. Labiris NR, Dolovich MB. Pulmonary drug delivery: part II. The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolised medications. Br J Clin Pharmacol 2003; 56 (6): 600-12
35. Lange CF, Finlay WH. Liquid atomizing: nebulizing and other methods of producing aerosols. J Aerosol Med 2006; 19 (1): 28-35
36. Bennett WD. Controlled inhalation of aerosolised therapeutics. Expert Opin Drug Deliv 2005; 2 (4): 763-7
37. Kleinstreuer C, Zhang Z. Targeted drug aerosol deposition analysis for a four-generation lung airway model with hemispherical tumors. J Biomech Eng 2003; 125 (2): 197-206
38. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005; 50 (9): 1161-76
39. Farkas A, Balashazy I, Szocs K. Characterization of regional and local deposition of inhaled aerosol drugs in the respiratory system by computational fluid particle dynamics methods. J Aerosol Med 2006; 19 (3): 329-43
40. Belmin J, Valensi P. Novel drug delivery systems for insulin: clinical potential for use in the elderly. Drugs Aging 2003; 20 (4): 303-12
41. Henry RR, Mudaliar S, Chu N, et al. Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol 2003; 43 (11): 1228-34
42. Tomoda K, Makino K. Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres. Colloids Surf B Biointerfaces 2007; 55 (1): 115-24
43. Videira MA, Botelho MF, Santos AC, et al. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002; 10 (8): 607-13
44. Rau JL. Practical problems with aerosol therapy in COPD. Respir Care 2006; 51 (2): 158-72
45. Yokoyama H, Yamamura Y, Ozeki T, et al. Analysis of relationship between peak inspiratory flow rate and amount of drug delivered to lungs following inhalation of fluticasone propionate with a Diskhaler® . Biol Pharm Bull 2007; 30 (1): 162-4
46. Borgstrom L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 2006; 19 (4): 473-83
47. Chan HK. Dry powder aerosol delivery systems: current and future research directions. J Aerosol Med 2006; 19 (1): 21-7
48. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006; 58 (9-10): 1030-60
49. Allen SC, Prior A. What determines whether an elderly patient can use a metered dose inhaler correctly? Br J Dis Chest 1986; 80 (1): 45-9
50. Dow L, Fowler L, Lamb H. Elderly people's technique in using dry powder inhalers: new inhaler devices are rarely used by older people in the community. BMJ 2001; 323 (7303): 49-50
51. Connolly M. Inhaler technique of elderly patients: comparison of metered-dose inhalers and large volume spacer devices. Age Ageing 1995; 24 (3): 190-2
52. Ho SF, Omahony MS, Steward JA, et al. Inhaler technique in older people in the community. Age Ageing 2004; 33 (2): 185-8
53. Jones V, Fernandez C, Diggory P. A comparison of large volume spacer, breath-activated and dry powder inhalers in older people. Age Ageing 1999; 28 (5): 481-4
54. Allen SC. Competence thresholds for the use of inhalers in people with dementia. Age Ageing 1997; 26 (2): 83-6
55. Allen SC, Ragab S. Ability to learn inhaler technique in relation to cognitive scores and tests of praxis in old age. Postgrad Med J 2002; 78 (915): 37-9
56. Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001; 322 (7286): 577-9
57. Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing 2003; 32 (3): 299-302
58. Board M, Allen SC. A simple drawing test to identify patients who are unlikely to be able to learn to use an inhaler. Int J Clin Pract 2006; 60 (5): 510-3
59. Armitage JM, Williams SJ. Inhaler technique in the elderly. Age Ageing 1988; 17 (4): 275-8
60. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing 2007; 36 (2): 213-8
61. Seki T, Kanbayashi H, Chono S, et al. Effects of a sperminated gelatin on the nasal absorption of insulin. Int J Pharm 2007; 338 (1-2): 213-8
62. Zhang QZ, Jiang XG, Wu CH. Distribution of nimodipine in brain following intranasal administration in rats. Acta Pharmacol Sin 2004; 25 (4): 522-7
63. Yamada K, Hasegawa M, Kametani S, et al. Nose-to-brain delivery of TS-002, a prostaglandin D2 analogue. J Drug Target 2007; 15 (1): 59-66
64. Tas C, Ozkan CK, Savaser A, et al. Nasal absorption of metoclopramide from different Carbopol 981 formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 2006; 64 (2): 246-54
65. Yu S, Zhao Y, Wu F, et al. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int J Pharm 2004; 281 (1-2): 11-23
66. Bhumkar DR, Joshi HM, Sastry M, et al. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res 2007; 24 (8): 1415-26
67. Cortesi R, Esposito E, Corradini F, et al. Non-phospholipid vesicles as carriers for peptides and proteins: production, characterization and stability studies. Int J Pharm 2007; 339 (1-2): 52-60
68. Li T, Lu WL, Hong HY, et al. Pharmacokinetics and anti-asthmatic potential of non-parenterally administered recombinant human interleukin-1 receptor antagonist in animal models. J Pharmacol Sci 2006; 102 (3): 321-30
69. Kumar TR, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol 2006; 7 (4): 261-76
70. Cleland JL, Daugherty A, Mrsny R. Emerging protein delivery methods. Curr Opin Biotechnol 2001; 12 (2): 212-9
71. Schuetz YB, Naik A, Guy RH, et al. Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2005; 2 (3): 533-48
72. Costello CT, Jeske AH. Iontophoresis: applications in transdermal medication delivery. Phys Ther 1995; 75 (6): 554-63
73. Dixit N, Bali V, Baboota S, et al. Iontophoresis: an approach for controlled drug delivery: a review. Curr Drug Deliv 2007; 4 (1): 1-10